Insights to the emerging potential of glucokinase activators as antidiabetic agent [0.03%]
glucokinase激活剂作为抗糖尿病药物的前景展望及启示
Anuradha Mehra,Shubham Kumar,Anu Mittal et al.
Anuradha Mehra et al.
The glucokinase enzyme (belongs to the hexokinase family) is present in liver cells and β-cells of the pancreas. Glucokinase acts as a catalyst in the conversion of glucose-6-phosphate from glucose which is rate-limiting step in glucose me...
Progression and expansion of quinoline as bioactive moiety: a patent review [0.03%]
喹啉作为生物活性基团的进展与扩展：专利回顾
Yash Chauhan,Kumari Neha,Sharad Wakode et al.
Yash Chauhan et al.
Quinoline inhibitors are appealing medicinal products for a range of illnesses and problems. It is bicyclic heterocyclic scaffold has been intensively employed in pharmacological research and is well known for its wide range of biological p...
Lipid-based mesoporous silica nanoparticles: a paradigm shift in management of pancreatic cancer [0.03%]
基于脂质的介孔二氧化硅纳米颗粒：胰腺癌管理中的范式转移
Kiran Kumar Bellapu,Ramesh Joga,Bharthi R Kannan et al.
Kiran Kumar Bellapu et al.
Pancreatic adenocarcinoma, a devastating disease, has the worst cancer prognosis in humans. It often develops resistance to common chemotherapy medications, such as gemcitabine, taxol and 5-fluorouracil. The dense stroma limits therapeutic ...
Luis Villafaña-Diaz,Juan C Perez-Garcia,Diana Barron-Villaverde et al.
Luis Villafaña-Diaz et al.
Aim: the activity of patent claims by Mexican pharmaceutical companies is unknown. Objective: analyse the trend in patents of Mexican pharmaceutical companies. Method: a search for patents was carried out in the patent database of the Mexic...
Proposed supplementary protection certificate legislation for medicinal products [0.03%]
关于医药产品的拟议补充保护证书立法
Olivia J Creemer,Stephen Garner
Olivia J Creemer
Sukhbir K Shahid
Sukhbir K Shahid
Leishmaniasis, a neglected tropical disease, is caused by protozoal parasites of the genus Leishmania. Clinical manifestations vary from asymptomatic to lethal grade depending on the type of the disease. The currently available antileishman...
Nemesio Villa-Ruano,Vianey Marin-Cevada,Gabriela Sanchez-Esgua et al.
Nemesio Villa-Ruano et al.
Repurposing of approved drugs allows strong savings in time and investment. Rimantadine is an FDA-approved drug for prevention and treatment of influenza A infection. Patent US2021330605 describes the use of rimantadine, an adamantane deriv...
Prominence of bioresponsive DNA nanococoons in tackling post-surgery cancer recurrence [0.03%]
生物响应性DNA纳米小包在治疗术后癌症复发中的重要作用
Sravani Yerram,Ramesh Joga,Pooja Shende et al.
Sravani Yerram et al.
Post-surgery cancer recurrence is one of the reasons for increased cancer cases. The effective usage of the enhanced permeability and retention effect of a nanocarrier infused with the bioresponsive release mechanism of checkpoint inhibitor...
Steroid sulfatase inhibitors and sulfated C19 steroids for proteotoxicity-related diseases: a patent spotlight [0.03%]
甾体硫酸化抑制剂和C19类固醇硫酸酯在蛋白毒性相关疾病中的应用：专利聚焦
Rami A Al-Horani
Rami A Al-Horani
Aging and proteotoxicity go hand in hand. Inhibiting proteotoxicity has been proposed to extend lifespan. This invention describes a new strategy to limit proteotoxicity and to extend the lifespan. Loss of function of sul-2, the Caenorhabdi...
Recent patent-based review on the role of three-dimensional printing technology in pharmaceutical and biomedical applications [0.03%]
基于近期专利的回顾：三维打印技术在制药和生物医学应用中的作用
Palak Rani,Vikas Yadav,Parijat Pandey et al.
Palak Rani et al.
Three-dimensional printing (3DP) is emerging as an innovative manufacturing technology for biomedical and pharmaceutical applications, since the US FDA approval of Spritam as a 3D-printed drug. In the present review, we have highlighted the...